AnaptysBio's rosnilimab fails Phase 2 UC trial; trial discontinued

ANAPTYSBIO, INC

Rosnilimab did not meet primary (mMS change) or key secondary endpoints at Week 12 in moderate-to-severe UC.
Clinical remission 7% for both doses vs 5% and 4% endoscopic remission; placebo rates within historical ranges.
Trial discontinued saving at least $10M; update on rosnilimab in RA expected H1 2026 via strategic capital.
Reaffirms 2026 separation of biopharma from royalty assets; Jemperli royalties >$390M/yr at peak sales >$2.7B.
Expects ~$300M cash end-2025 including $75M milestone from GSK for Jemperli reaching $1B global net sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.